Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 0.97 0.57% 0.01
ALNA closed up 0.57 percent on Friday, September 17, 2021, on 42 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical ALNA trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 0.57%
NR7 Range Contraction 0.57%
Stochastic Reached Oversold Weakness 0.57%
Oversold Stochastic Weakness 0.57%
20 DMA Resistance Bearish 1.04%
Fell Below 50 DMA Bearish 1.04%
Older End-of-Day Signals for ALNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Allena Pharmaceuticals, Inc. Description

Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Gastrointestinal Kidney Diseases Orphan Disease Orphan Diseases Crystals Hyperoxaluria Chronic Management

Is ALNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.77
52 Week Low 0.75
Average Volume 3,450,474
200-Day Moving Average 1.30
50-Day Moving Average 0.96
20-Day Moving Average 1.00
10-Day Moving Average 1.02
Average True Range 0.06
ADX 16.14
+DI 21.43
-DI 17.78
Chandelier Exit (Long, 3 ATRs) 0.93
Chandelier Exit (Short, 3 ATRs) 0.99
Upper Bollinger Bands 1.11
Lower Bollinger Band 0.88
Percent B (%b) 0.39
BandWidth 22.38
MACD Line 0.00
MACD Signal Line 0.01
MACD Histogram -0.0067
Fundamentals Value
Market Cap 37.14 Million
Num Shares 38.3 Million
EPS -2.01
Price-to-Earnings (P/E) Ratio -0.48
Price-to-Sales 0.00
Price-to-Book 3.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.06
Resistance 3 (R3) 1.07 1.04 1.04
Resistance 2 (R2) 1.04 1.02 1.04 1.04
Resistance 1 (R1) 1.01 1.01 1.00 1.00 1.03
Pivot Point 0.98 0.98 0.98 0.98 0.98
Support 1 (S1) 0.95 0.96 0.94 0.94 0.91
Support 2 (S2) 0.92 0.95 0.92 0.90
Support 3 (S3) 0.89 0.92 0.90
Support 4 (S4) 0.88